BACKGROUND: A distinction between symptomatic non-erosive reflux disease (NERD) and erosive esophagitis (EE) patients is supported by the presence of inflammatory response in the mucosa of EE patients, leading to a damage of mucosal integrity. To explore the underlying mechanism of this difference, we assessed inflammatory mediators in mucosal biopsies from EE and NERD patients and compared them with controls. METHODS: Nineteen NERD patients, 15 EE patients, and 16 healthy subjects underwent endoscopy after a 3-week washout from PPI or H(2) antagonists. Biopsies obtained from the distal esophagus were examined by quantitative real-time polymerase chain reaction (qPCR) and multiplex enzyme-linked immunosorbent assay for selected chemokines and lyso-PAF acetyltransferase (LysoPAF-AT), the enzyme responsible for production of platelet-activating factor (PAF). KEY RESULTS: Expression of LysoPAF-AT and multiple chemokines was significantly increased in mucosal biopsies derived from EE patients, when compared with NERD patients and healthy controls. Upregulated chemokines included interleukin 8, eotaxin-1, -2, and -3, macrophage inflammatory protein-1α (MIP-1α), and monocyte chemoattractant protein-1 (MCP-1). LysoPAF-AT and the chemokine profile in NERD patients were comparable with healthy controls. CONCLUSIONS & INFERENCES: Levels of selected cytokines and Lyso-PAF AT were significantly higher in the esophageal mucosa of EE patients compared with NERD and control patients. This difference may explain the distinct inflammatory response occurring in EE patients' mucosa. In contrast, as no significant differences existed between the levels of all mediators in NERD and control subjects, an inflammatory response does not appear to play a major role in the pathogenesis of the abnormalities found in NERD patients.
BACKGROUND: A distinction between symptomatic non-erosive reflux disease (NERD) and erosive esophagitis (EE) patients is supported by the presence of inflammatory response in the mucosa of EE patients, leading to a damage of mucosal integrity. To explore the underlying mechanism of this difference, we assessed inflammatory mediators in mucosal biopsies from EE and NERD patients and compared them with controls. METHODS: Nineteen NERD patients, 15 EE patients, and 16 healthy subjects underwent endoscopy after a 3-week washout from PPI or H(2) antagonists. Biopsies obtained from the distal esophagus were examined by quantitative real-time polymerase chain reaction (qPCR) and multiplex enzyme-linked immunosorbent assay for selected chemokines and lyso-PAF acetyltransferase (LysoPAF-AT), the enzyme responsible for production of platelet-activating factor (PAF). KEY RESULTS: Expression of LysoPAF-AT and multiple chemokines was significantly increased in mucosal biopsies derived from EE patients, when compared with NERD patients and healthy controls. Upregulated chemokines included interleukin 8, eotaxin-1, -2, and -3, macrophage inflammatory protein-1α (MIP-1α), and monocyte chemoattractant protein-1 (MCP-1). LysoPAF-AT and the chemokine profile in NERD patients were comparable with healthy controls. CONCLUSIONS & INFERENCES: Levels of selected cytokines and Lyso-PAF AT were significantly higher in the esophageal mucosa of EE patients compared with NERD and control patients. This difference may explain the distinct inflammatory response occurring in EE patients' mucosa. In contrast, as no significant differences existed between the levels of all mediators in NERD and control subjects, an inflammatory response does not appear to play a major role in the pathogenesis of the abnormalities found in NERD patients.
Authors: M P L Guarino; L Cheng; J Ma; K Harnett; P Biancani; A Altomare; F Panzera; J Behar; M Cicala Journal: Neurogastroenterol Motil Date: 2010-05-06 Impact factor: 3.598
Authors: Carine Blanchard; Emily M Stucke; Beatriz Rodriguez-Jimenez; Karen Burwinkel; Margaret H Collins; Annette Ahrens; Eileen S Alexander; Bridget K Buckmeier Butz; Sean C Jameson; Ajay Kaul; James P Franciosi; Jonathan P Kushner; Philip E Putnam; J Pablo Abonia; Marc E Rothenberg Journal: J Allergy Clin Immunol Date: 2011-01 Impact factor: 10.793
Authors: S Jyonouchi; C L Smith; F Saretta; V Abraham; K R Ruymann; P Modayur-Chandramouleeswaran; M-L Wang; J M Spergel; A Cianferoni Journal: Clin Exp Allergy Date: 2014-01 Impact factor: 5.018
Authors: Kerry B Dunbar; Agoston T Agoston; Robert D Odze; Xiaofang Huo; Thai H Pham; Daisha J Cipher; Donald O Castell; Robert M Genta; Rhonda F Souza; Stuart J Spechler Journal: JAMA Date: 2016-05-17 Impact factor: 56.272
Authors: Mahboobeh Mahdavinia; Faraz Bishehsari; Waqas Hayat; Christopher D Codispoti; Shahram Sarrafi; Inna Husain; Arpita Mehta; Mohamed Benhammuda; Mary C Tobin; Sindhura Bandi; Philip S LoSavio; Jill S Jeffe; Erica L Palmisano; Robert P Schleimer; Pete S Batra Journal: Ann Allergy Asthma Immunol Date: 2016-06-07 Impact factor: 6.347
Authors: Nicolaas F Rinsma; Ricard Farré; Fred J Troost; Montserrat Elizalde; Daniel Keszthelyi; Zsuzsanna Helyes; Ad A Masclee; José M Conchillo Journal: Int J Mol Sci Date: 2017-05-19 Impact factor: 5.923